<SEC-DOCUMENT>0001178913-26-000804.txt : 20260310
<SEC-HEADER>0001178913-26-000804.hdr.sgml : 20260310
<ACCEPTANCE-DATETIME>20260310080748
ACCESSION NUMBER:		0001178913-26-000804
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260310
DATE AS OF CHANGE:		20260310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRINITY BIOTECH PLC
		CENTRAL INDEX KEY:			0000888721
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-293717
		FILM NUMBER:		26737285

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		IDA BUSINESS PARK
		STREET 2:		BRAY
		CITY:			WICKLOW
		PROVINCE COUNTRY:   	L2
		BUSINESS PHONE:		01135312955111

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		IDA BUSINESS PARK
		STREET 2:		BRAY
		CITY:			WICKLOW
		PROVINCE COUNTRY:   	L2
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>zk2634506.htm
<DESCRIPTION>424B3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z39ceaa947a1b49feb7b7e15a4ed75774" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">Prospectus Supplement No. 1</div>
          </td>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">Filed Pursuant to Rule 424(b)(3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">(To Prospectus dated March 04, 2026)</div>
          </td>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 33.33%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">Registration No. 333-293717</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z8a2c31cfe8004d178845f27ab6a0ed34" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 76%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">TRINITY BIOTECH PLC</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Secondary offering of up to</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">35,282,966 American Depositary Shares</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">representing</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">705,659,320 Ordinary Shares</div>
          </td>
          <td style="width: 12%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus supplement updates and supplements the information contained in the prospectus dated March 04, 2026 (as may be supplemented or amended from time to time, the
      &#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form F-1, with information contained in our Reports on Form 6-K, which were filed with the Securities and Exchange Commission on March 10, 2026 (the &#8220;Current Reports&#8221;). Accordingly,
      we have attached the Current Reports to this prospectus supplement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The prospectus, as it may be amended or supplemented from time to time, relates to the offer and resale by the Selling Shareholders from time to time of up to 705,659,320 Ordinary
      Shares, represented by up to 35,282,966 ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol &#8220;TRIB.&#8221; The last reported sale price of our ADSs on March 9, 2026 was $0.7010.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">You should read the Prospectus, this prospectus supplement and any additional prospectus supplement or amendment carefully before you invest in our securities.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our business and an investment in our ADSs involve significant risks. These risks are described under the caption &#8220;Risk Factors&#8221; beginning on page 5 of the
      Prospectus and any other risk factors contained in any applicable prospectus supplement and in the documents incorporated by reference into the Prospectus.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or
      adequacy of this prospectus. Any representation to the contrary is a criminal offense.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> The date of this prospectus supplement is March 10, 2026.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div>
        <div style="text-align: center;">
          <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">SECURITIES
            AND EXCHANGE COMMISSION</div>
          <div style="line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549</div>
          <div style="line-height: 1.25; font-weight: bold;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">F O R M&#160;6-K</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
          <div style="line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
          <div style="line-height: 1.25; font-weight: bold;">For the month of March 2026</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">TRINITY
            BIOTECH PLC</div>
          <div style="line-height: 1.25;">(Name of Registrant)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">IDA Business Park</div>
          <div style="line-height: 1.25;">Bray, Co. Wicklow, Ireland</div>
          <div style="line-height: 1.25;">(Address of Principal Executive Office)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).</div>
          <div style="line-height: 1.25; font-weight: bold;"> <br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">&#160;<font style="font-weight: bold;">EXPLANATORY NOTE</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">
              <div style="line-height: 1.25; text-align: left;">On March 10, 2026, the Company issued a press release announcing further major technical breakthroughs in advancing its Next Generation CGM+ Platform. A copy of the press release is filed
                herewith as Exhibit 99.1.</div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="2" border="0" id="z51f407040fc84f058790bf4d2c202e1c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 6.52%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="line-height: 1.25;">Exhibit</div>
                </td>
                <td style="width: 2%; vertical-align: top;">&#160;</td>
                <td style="width: 94%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; line-height: 1.25;">Description</div>
                </td>
              </tr>
              <tr>
                <td style="width: 6.52%; vertical-align: top;">
                  <div style="line-height: 1.25;"><a href="#A99.">99.1</a></div>
                </td>
                <td style="width: 2%; vertical-align: top;">
                  <div style="line-height: 1.25;"><br>
                  </div>
                </td>
                <td style="width: 94%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">
                    <div style="text-align: left; line-height: 1.25;"><a href="#A99.">Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform</a></div>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">SIGNATURES</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
            authorized.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z9291573a99804e9dab290d5a16643ef7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 32.46%; vertical-align: top;" colspan="2">
                  <div style="text-align: justify; line-height: 1.25;"><u>TRINITY BIOTECH PLC</u></div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 29.37%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Trinity Biotech plc</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 29.37%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">(Registrant)</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 29.37%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">By:</div>
                </td>
                <td style="width: 29.37%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="text-align: justify; line-height: 1.25;">/s/ Paul Murphy</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 29.37%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Paul Murphy</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 49.79%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.09%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 29.37%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Interim Chief Financial Officer</div>
                </td>
                <td style="width: 17.76%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">Date:&#160; March 10, 2026</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1<a name="A99."><!--Anchor--></a></font></u> </div>
          <div style="line-height: 1.25; text-align: right;"><img height="61" width="229" src="image00001.jpg"></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold; text-align: left;">CONFIDENTIAL UNTIL RELEASED</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" border="0" id="z1494583212ba46a2a6039eb7715c1334" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

                <tr>
                  <td style="width: 15%;">
                    <div>Contact: <br>
                    </div>
                  </td>
                  <td style="width: 35%;">
                    <div> <font style="font-weight: bold;">Trinity Biotech plc</font>&#160;&#160;&#160; <br>
                    </div>
                  </td>
                  <td style="width: 45%;">
                    <div><font style="font-weight: bold;">RedChip Companies Inc.</font>&#160; <br>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 15%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 35%;">
                    <div>Gary Keating, PhD&#160;&#160; <br>
                    </div>
                  </td>
                  <td style="width: 45%;">
                    <div>
                      <div style="line-height: 1.25;">Dave Gentry, CEO</div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 15%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 35%; vertical-align: top;">
                    <div>(353)-1-2769800&#160; <br>
                    </div>
                  </td>
                  <td style="width: 45%;">
                    <div>
                      <div style="line-height: 1.25;">(1)-407-644-4256</div>
                      <div style="line-height: 1.25;">(1)-800-RED-CHIP (733-2447)</div>
                      <div style="line-height: 1.25;"><u>TRIB@redchip.com</u></div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Trinity
              Biotech Announces Further Major Technical </div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Breakthroughs






              in Advancing Next Generation CGM+ Platform</div>
          </div>
          <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"> <br>
            </font></div>
          <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization</div>
          <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;"> <br>
          </div>
          <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">
            <div style="font-family: 'Times New Roman', Times, serif; font-style: italic;">- Anticipating initiation of pivotal clinical trial in 2026</div>
            <div style="font-family: 'Times New Roman', Times, serif; font-style: italic;"> <br>
            </div>
            <div style="font-family: 'Times New Roman', Times, serif; font-style: italic;">
              <div style="font-style: italic;">- Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a material</div>
              <div style="font-style: italic;"> reduction in MARD across multi-day wear</div>
              <div style="font-style: italic;"> <br>
              </div>
              <div style="font-style: italic;">
                <div style="font-style: italic;">- Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights</div>
                <div style="font-style: italic;"> <br>
                </div>
                <div style="font-style: italic;">
                  <div style="font-style: italic;">- CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versus </div>
                  <div style="font-style: italic;">current market-leading CGMs</div>
                  <div style="font-style: italic;"> <br>
                  </div>
                  <div>
                    <div style="font-style: italic;">- Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sectors</div>
                    <div style="font-style: italic;"> <br>
                    </div>
                    <font style="font-family: 'Times New Roman',Times,serif;"> </font>
                    <div style="text-align: justify; line-height: 1.25;">
                      <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: normal;">DUBLIN, Ireland and OREGON, United States of America (XXXX, 2026) -</font><font style="font-style: normal;"> Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a number of significant
                          technical advancements in the development of its next-generation, finger-stick calibration-free Continuous Glucose Monitoring (CGM) system, CGM+, marking a major step toward bringing the technology to global markets.</font></div>
                    </div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="line-height: 1.25; text-align: left; font-style: normal;">John Gillard, Trinity Biotech President &amp; Chief Executive Officer, commented:</div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-style: italic;">&#8220;These are some of the most important technical advancements to date in our CGM+ development program. The glucose measurement accuracy gains achieved by the
                      incorporation of key components of our enhanced electronics architecture gives us strong conviction to accelerate into pivotal trials this year. The fact that these enhanced electronic components also underpin our innovative
                      multi-modal sensing architecture gives us a valuable foundation from which we intend to deliver a truly differentiated device, CGM+, to key markets globally.</div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Metabolic health problems sit at the center of the world&#8217;s disease burden, with rising incidence of obesity, diabetes, hypertension, and related cardiometabolic
                      disorders. In everyday life, metabolic health shapes how we perform, recover, and age. Key metabolic health factors include glucose levels, activity, sleep, and stress - metrics that are measurable and personalized. Using AI-native
                      health monitoring, CGM+ is being designed to translate these metrics into powerful insights to support better metabolic health.</div>
                    <div style="text-align: justify; line-height: 1.25; font-style: italic;"> <br>
                    </div>
                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Our innovation agenda is central to our growth ambitions at Trinity Biotech, and our latest results highlight our commitment to deliver industry-leading
                      innovation, precision, and quality. We are excited with what we have achieved, and we are increasingly confident that CGM+ provides Trinity Biotech with the platform to deliver a significant step-change in the growth and scale of the
                      company. We look forward to initiating a pivotal clinical trial and bringing this important solution to market.&#8221;</div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: normal;">The Company has collected more than 650 days of clinical testing data across a number of trials on an updated glucose
                      sensor architecture which has now been integrated with key next-generation electronic components. The updated system delivered a substantial improvement in glucose measurement accuracy across multi-day wear, achieving a <font style="font-family: 'Times New Roman', Times, serif;">material</font> reduction in Mean Absolute Relative Difference (MARD) compared to prior clinical studies of the upgraded glucose sensor.&#160; These results now provide strong <font style="font-family: 'Times New Roman', Times, serif;">evidence</font> that the upgraded system can meet the industry standards for glucose measurement accuracy of modern CGMs.</div>
                    <div style="line-height: 1.25; font-style: normal;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-style: normal;">The</font><font style="font-style: normal;"> new electronics also underpin CGM+&#8217;s unique multimodal
                        data-capture capabilities, which are designed to support advanced, AI-driven analytical models. Utilizing this multimodal approach, the Company aims to position CGM+ not only as a glucose sensor, but as an important enabling
                        platform for broader AI-enhanced digital health, with a particular focus on personalized metabolic health insights.</font></div>
                    <div style="line-height: 1.25; font-style: normal;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-style: normal;">The next-generation</font><font style="font-style: normal;"> components are also critical to enabling the
                        CGM+ device&#8217;s user-friendly modular design which drives significant cost and sustainability benefits compared to current market leading CGMs. The cost of current CGM solutions remains one of the main barriers to broader adoption of
                        this important technology.</font></div>
                    <div style="line-height: 1.25; font-style: normal;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: normal;">In addition, Trinity Biotech has conducted successful trials on an updated needle-free glucose sensor insertion
                      process. This new insertion process is fundamental to the next<font style="font-family: 'Times New Roman', Times, serif;">&#8209;</font>generation, user-friendly modular design and is <font style="font-family: 'Times New Roman', Times, serif;">yet </font>another important milestone in confirming the technical viability of the updated device design.</div>
                    <div style="line-height: 1.25; font-style: normal;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-style: normal;">The Company believes that these</font><font style="font-style: normal;"> breakthrough results
                        significantly strengthen the device&#8217;s technical readiness, reduce system level risk, and support the progression of CGM+ toward regulatory submissions and scaled commercialization. CGM+ has the potential to make high quality
                        metabolic intelligence more affordable, more intuitive, and more widely available than ever before.</font></div>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25; font-weight: bold; text-align: left; font-style: normal;">Anticipating Initiation of Pivotal Clinical Trial In 2026</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">Since the unveiling of CGM+ in July 2025, Trinity Biotech has continued to innovate and refine this next-generation biosensor platform. Prior breakthrough results
                      released in August 2025 on its redesigned proprietary needle-free glucose sensor, confirmed the elimination of the requirement for finger-stick calibration and de-risked the commercialization pathway for CGM+.</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">
                      <div style="line-height: 1.25;">The Company is collaborating with clinicians, scientists, user groups, and digital health leaders to further optimize its innovative multi-sensor CGM+ architecture which is being designed to collect
                        multiple selected physiological metrics alongside glucose in a single modular device.</div>
                    </div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">Advanced AI&#8209;native analytics will transform this complex, multifactorial data into personalized and actionable insights, giving CGM+ users a seamless connected
                      experience and clinicians a powerful treatment tool.</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">
                      <div style="line-height: 1.25;">Based upon enthusiastic feedback from key stakeholders and given the strength of these recent clinical trial results, Trinity Biotech is now advancing the CGM+ program through the final design phase and
                        anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets immediately thereafter.</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                    </div>
                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                      <div style="page-break-after: always;" class="BRPFPageBreak">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">
                      <div style="line-height: 1.25;">CGM+ is uniquely positioned at the confluence of advanced glucose monitoring technology, AI-native healthcare analytics, and increasing demand for AI wearables. Market dynamics indicate strong growth in
                        these already sizeable markets and recent forecasts predict strong growth in the coming years:</div>
                    </div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11eae36e93e043b998c3de967ecbee9a">

                        <tr>
                          <td style="width: 18pt;"><font style="font-style: normal;"><br>
                            </font> </td>
                          <td style="width: 18pt; vertical-align: top; font-style: normal;">&#8226;</td>
                          <td style="width: auto; vertical-align: top;">
                            <div style="font-style: normal;">Global CGM Market: Projected to grow from $15.3B in 2026 to $31.4B by 2031 (CAGR: 15.4%)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
                          </td>
                        </tr>

                    </table>
                    <font style="font-style: normal;"> </font>
                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3355d8fafc7042c6928b16b338a2e08e">

                        <tr>
                          <td style="width: 18pt;"><font style="font-style: normal;"><br>
                            </font> </td>
                          <td style="width: 18pt; vertical-align: top; font-style: normal;">&#8226;</td>
                          <td style="width: auto; vertical-align: top;">
                            <div style="font-style: normal;">AI in Healthcare: Forecast to reach approximately $250B by 2031, growing at a 35.7% CAGR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
                          </td>
                        </tr>

                    </table>
                    <font style="font-style: normal;"> </font>
                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbfb3c9fa2d184124bff1c2157d912a7f">

                        <tr>
                          <td style="width: 18pt;"><font style="font-style: normal;"><br>
                            </font> </td>
                          <td style="width: 18pt; vertical-align: top; font-style: normal;">&#8226;</td>
                          <td style="width: auto; vertical-align: top;">
                            <div style="font-style: normal;">Wearable AI: Expected to reach $360B by 2034, growing at a 24.7% CAGR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup></div>
                          </td>
                        </tr>

                    </table>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <div style="text-align: left;"><font style="font-family: 'Times New Roman',Times,serif; font-style: normal;">For more information on CGM+ please visit our dedicated website <u>https://cgm.trinitybiotech.com/</u></font><font style="font-style: normal;"><br style="line-height: 1.25;">
                        <br style="line-height: 1.25;">
                      </font></div>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>https://www.mordorintelligence.com/industry-reports/continuous-glucose-monitoring-market</div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>&#160;https://www.mordorintelligence.com/industry-reports/artificial-intelligence-in-healthcare-market</div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup>&#160;https://www.fortunebusinessinsights.com/wearable-ai-market-109561</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25; font-weight: bold; text-align: left; font-style: normal;">Forward-Looking Statements</div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-style: normal;">This release includes statements that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (the
                      &#8220;Reform Act&#8221;), including but not limited to statements related to Trinity Biotech&#8217;s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future
                      recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms
                      &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;projects,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties,
                      including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the
                      impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company&#8217;s
                      distributors, losses or system failures with respect to Trinity Biotech&#8217;s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results,
                      dependence on suppliers, the market acceptance of Trinity Biotech&#8217;s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on
                      a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity
                      Biotech&#8217;s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under &#8220;Risk Factors&#8221; in Trinity
                      Biotech&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech&#8217;s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking
                      statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;"><font style="font-style: normal;"><br style="line-height: 1.25;">
                      </font> </div>
                    <font style="font-style: normal;"> </font>
                    <div style="text-align: justify; line-height: 1.25; font-weight: bold; font-style: normal;">About Trinity Biotech</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25; font-style: normal;">&#160;</div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25; text-align: left; font-style: normal;">Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company
                      develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable
                      biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our
                      products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of
                      international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: <u>www.trinitybiotech.com</u>.</div>
                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                      <div style="page-break-after: always;" class="BRPFPageBreak">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div> <br>
                    </div>
                    <div style="line-height: 1.25; text-align: left; font-style: normal;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
                      </div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">F O R M&#160;6-K</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of March 2026</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">TRINITY BIOTECH PLC</div>
                      <div style="text-align: center; line-height: 1.25;">(Name of Registrant)</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25;">IDA Business Park</div>
                      <div style="text-align: center; line-height: 1.25;">Bray, Co. Wicklow, Ireland</div>
                      <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Office)</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="line-height: 1.25; font-weight: bold;">
                        <div style="line-height: 1.25; font-weight: bold;">
                          <div style="line-height: 1.25; font-weight: bold;">This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).</div>
                        </div>
                      </div>
                      <div style="line-height: 1.25; font-weight: bold;"> <br>
                      </div>
                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25;">&#160;<font style="font-weight: bold;">EXPLANATORY NOTE</font></div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">On March 10, 2026, the Company issued a press release providing a trading and business update. A copy of the press release is filed herewith as Exhibit 99.1.</div>
                        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                        </div>
                        <div style="margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">In connection with the trading and business update, the Company has obtained a limited waiver in respect of covenant 8.16 of its Credit Agreement with
                          Perceptive Credit Holdings III and has obtained a deferral in respect of the scheduled change in covenant 8.15 of the Credit Agreement, both through July 1, 2026.</div>
                        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                        </div>
                      </div>
                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                          <tr>
                            <td style="width: 6.52%; vertical-align: top; border-bottom: #000000 2px solid;">
                              <div style="line-height: 1.25;">Exhibit</div>
                            </td>
                            <td style="width: 2%; vertical-align: top;"><br>
                            </td>
                            <td style="width: 94%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                              <div style="text-align: justify; line-height: 1.25;">Description</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 6.52%; vertical-align: top;">
                              <div style="line-height: 1.25;"><a href="#Exhibit99">99.1</a></div>
                            </td>
                            <td style="width: 2%; vertical-align: top;"><br>
                            </td>
                            <td style="width: 94%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;"><a href="#Exhibit99">Trinity Biotech Provides Business and Trading Update</a></div>
                            </td>
                          </tr>

                      </table>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: center; line-height: 1.25;">SIGNATURES</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
                        thereunto duly authorized.</div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 32.46%; vertical-align: top;" colspan="2">
                              <div style="text-align: justify; line-height: 1.25;"><u>TRINITY BIOTECH PLC</u></div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;">Trinity Biotech plc</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;">(Registrant)</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;">By:</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top; border-bottom: #000000 2px solid;">
                              <div style="text-align: justify; line-height: 1.25;">/s/ Paul Murphy</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;">Paul Murphy</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 49.79%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 3.09%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                            <td style="width: 29.37%; vertical-align: top;">
                              <div style="text-align: justify; line-height: 1.25;">Interim Chief Financial Officer</div>
                            </td>
                            <td style="width: 17.76%; vertical-align: top;">
                              <div style="line-height: 1.25;">&#160;</div>
                            </td>
                          </tr>

                      </table>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="text-align: justify; line-height: 1.25;">Date:&#160; March 10, 2026</div>
                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <div>
                        <div style="text-align: center;">
                          <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
                          </div>
                          <div style="line-height: 1.25;"><img height="61" width="229" src="image00001.jpg"></div>
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="line-height: 1.25;">
                              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                                  <tr>
                                    <td style="width: 15%;">
                                      <div>Contact: <br>
                                      </div>
                                    </td>
                                    <td style="width: 35%;">
                                      <div> <font style="font-weight: bold;">Trinity Biotech plc</font>&#160;&#160;&#160; <br>
                                      </div>
                                    </td>
                                    <td style="width: 45%;">
                                      <div><font style="font-weight: bold;">RedChip Companies Inc.</font>&#160; <br>
                                      </div>
                                    </td>
                                  </tr>
                                  <tr>
                                    <td style="width: 15%;">
                                      <div>&#160;</div>
                                    </td>
                                    <td style="width: 35%;">
                                      <div>
                                        <div style="text-align: left; line-height: 1.25;">Paul Murphy</div>
                                      </div>
                                    </td>
                                    <td style="width: 45%;">
                                      <div>
                                        <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Dave Gentry, CEO</font></div>
                                      </div>
                                    </td>
                                  </tr>
                                  <tr>
                                    <td style="width: 15%;">
                                      <div>&#160;</div>
                                    </td>
                                    <td style="width: 35%; text-align: left; vertical-align: top;">
                                      <div><font style="font-family: 'Times New Roman',Times,serif;">(353)-1-2769800</font>&#160; <br>
                                      </div>
                                    </td>
                                    <td style="width: 45%;">
                                      <div>
                                        <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(1)-407-644-4256</font></div>
                                        <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(1)-800-RED-CHIP (733-2447)</font></div>
                                        <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>TRIB@redchip.com</u></font></div>
                                      </div>
                                    </td>
                                  </tr>

                              </table>
                            </div>
                            <div style="line-height: 1.25;"><br>
                            </div>
                          </div>
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Trinity Biotech Provides Business and Trading Update</div>
                          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                          </div>
                          <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;"><font style="font-weight: bold;">DUBLIN, Ireland (DRAFT March XX, 2026) -</font>&#160;Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology
                            company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an update on its trading activities for Quarter 4, 2025 and some key business updates.</div>
                          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                          </div>
                          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Trading Update</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="line-height: 1.25">
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 18.75pt;"><br>
                                  </td>
                                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                    <div>The Company expects Quarter 4, 2025 revenue within the range of approximately $11.5 million to $12.5 million.</div>
                                  </td>
                                </tr>

                            </table>
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 18.75pt;"><br>
                                  </td>
                                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                    <div>This compares to Quarter 4, 2024 revenue of $15.9 million, which was driven by a substantial increase in TrinScreen&#8482; HIV sales from $0.4 million in Quarter 4, 2023 to $3.2 million in Quarter 4, 2024.</div>
                                  </td>
                                </tr>

                            </table>
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 18.75pt;"><br>
                                  </td>
                                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                    <div>The reduction in revenue between Quarter 4, 2024 and Quarter 4, 2025 was primarily driven by:</div>
                                  </td>
                                </tr>

                            </table>
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 54.75pt;"><br>
                                  </td>
                                  <td style="width: 18pt; vertical-align: top;">o</td>
                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                    <div>The residual impact of the disruption to the global health market for HIV testing in 2025 due to changes affecting international aid funding structures, and</div>
                                  </td>
                                </tr>

                            </table>
                            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                <tr>
                                  <td style="width: 54.75pt;"><br>
                                  </td>
                                  <td style="width: 18pt; vertical-align: top;">o</td>
                                  <td style="width: auto; vertical-align: top; text-align: justify;">
                                    <div>The fine-tuning of manufacturing and supply-chain processes to accommodate the rise in demand for TrinScreen&#8482; HIV in late 2025 as the Company transitioned to&#160;outsourced manufacturing under the Company&#8217;s
                                      Comprehensive Transformation Plan.</div>
                                  </td>
                                </tr>

                            </table>
                          </div>
                          <br>
                          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Business Update</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">The Company&#8217;s key strategic objectives are to grow the existing business profitably and to advance its exciting innovation agenda, including the flagship
                            development CGM+. As such, the Company continues to focus on, and make substantial progress in, its Comprehensive Transformation Plan, which is designed to substantially improve the long-term profitability of the Company&#8217;s
                            existing business lines.</div>
                          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                          </div>
                          <div style="line-height: 1.25;">
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">The Company has recently secured several key regulatory approvals, including in February 2026, local regulatory approval for outsourcing and offshoring
                              the production of its Uni-Gold&#8482; HIV rapid test. The receipt of this regulatory approval allows the Company to proceed with the final transition of Uni-Gold manufacturing and, as previously announced, this key aspect of its
                              Comprehensive Transformation Plan is being prioritised during the first quarter of 2026.</div>
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">In addition to pursuing profitability focused operational transformation, such as the finalisation of outsourced manufacturing, the Company continues to
                              focus on commercialisation of its rapid HIV test franchise and this is underpinned by renewed strength in global HIV testing demand.&#160;In particular, the Company is seeing strong demand for Uni-Gold&#8482; HIV. As the Company gains
                              continued commercial traction with TrinScreen&#8482; and sees improved Uni-Gold&#8482; HIV demand, it is expected that Rapid HIV will be a larger proportion of the Company&#8217;s revenue base in 2026.</div>
                            <br>
                          </div>
                          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                            <div class="BRPFPageBreak" style="page-break-after: always;">
                              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                          </div>
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">
                              <div style="margin-left: 0.75pt; line-height: 1.25;">Given the nature of global health HIV test procurement, where order timing and size can vary significantly, and in particular the typical scale of TrinScreen&#8482; orders, the
                                Company expects a higher degree of quarter-on-quarter revenue variability. The move to outsourced manufacturing for its Uni-Gold&#8482; HIV and TrinScreen&#8482; products is intended to mitigate the profitability impact of this
                                increased revenue variability by transitioning a significant portion of the continuing cost base from fixed cost to variable costs, though the transition to outsourcing itself will also temporarily introduce a further degree
                                of quarter-on-quarter revenue variability in the first half of 2026. As a result of these factors, the Company now anticipates that some HIV revenue will shift from Quarter 1 into Quarter 2 and also from Quarter 2 into
                                Quarter 3, shifting the cadence of quarterly profitability and cashflows as the Company stays firmly focused on full&#8209;year and long&#8209;term performance, in line with its strategic objectives.</div>
                            </div>
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">The Company also continues to focus on the execution of its multi-facetted business improvement plan for its diabetes care Premier Hb9210 HbA1c laboratory
                              blood glucose monitoring solution. Having secured the prestigious Gold Classification from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) for 2026, and obtained regulatory clearances in
                              multiple countries for the expanded rollout of its next-generation high-capacity HbA1c column system, the Company is now focusing on increasing commercial efforts for this upgraded HbA1c column system.</div>
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">These commercial efforts are focused on building new sales relationships in the US and Brazil where the Company has a direct sales presence.&#160; The Company
                              is also now building new and expanded relationships with third party distributors in other territories, as this product line is positioned for renewed long-term growth. The upgraded column system builds upon broader
                              improvement initiatives in the Company&#8217;s haemoglobin business, including the transition of certain manufacturing processes to other group manufacturing sites to increase manufacturing capacity and to reduce costs as part of
                              its profitability focused Comprehensive Transformation Plan.</div>
                            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                            </div>
                            <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">The Company is confident that these product development, commercial and operational developments, coupled with rising global diabetes prevalence, position
                              this business for long-term profitable growth, again consistent with the Company&#8217;s overall strategic objectives.</div>
                          </div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Pipeline Developments</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;">The Company continues to advance its key strategic growth projects currently in development, including:</div>
                          <div style="text-align: justify; margin-left: 0.75pt; line-height: 1.25;"> <br>
                          </div>
                          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                              <tr>
                                <td style="width: 18.75pt;"><br>
                                </td>
                                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                  <div>Its next-generation continuous glucose monitor, CGM+;</div>
                                </td>
                              </tr>

                          </table>
                          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                              <tr>
                                <td style="width: 18.75pt;"><br>
                                </td>
                                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                  <div>EpiCapture, the company&#8217;s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease; and</div>
                                </td>
                              </tr>

                          </table>
                          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                              <tr>
                                <td style="width: 18.75pt;"><br>
                                </td>
                                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                                <td style="width: auto; vertical-align: top; text-align: justify;">
                                  <div>PrePsia&#8482;, an innovative early pregnancy screening test designed to assess the risk of preeclampsia&#8212;a potentially life-threatening condition for both mother and baby.</div>
                                </td>
                              </tr>

                          </table>
                          <div style="line-height: 1.25">&#160;</div>
                          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                            <div class="BRPFPageBreak" style="page-break-after: always;">
                              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                          </div>
                          <div style="line-height: 1.25"> <br>
                          </div>
                          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; line-height: 1.25;">This release includes statements that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (the &#8220;Reform Act&#8221;),
                            including but not limited to statements related to Trinity Biotech&#8217;s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring
                            revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms
                            &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;projects,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties,
                            including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future,
                            our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech,
                            potential excess inventory levels and inventory imbalances at the company&#8217;s distributors, losses or system failures with respect to Trinity Biotech&#8217;s facilities or manufacturing operations, the effect of exchange rate
                            fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech&#8217;s products and services, the continuing development of its products,
                            required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks
                            associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech&#8217;s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related
                            to condition of the United States economy and other risks detailed under &#8220;Risk Factors&#8221; in Trinity Biotech&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech&#8217;s other periodic reports
                            filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any
                            obligation to update any forward-looking statements.</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Trinity Biotech</div>
                          <div style="line-height: 1.25">&#160;</div>
                          <div style="text-align: justify; line-height: 1.25;">Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops,
                            acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor
                            industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products
                            are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of
                            international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: <u>www.trinitybiotech.com</u>.</div>
                        </div>
                      </div>
                    </div>
                    <div style="line-height: 1.25; text-align: left; font-style: normal;"> <br>
                    </div>
                    <font style="font-style: normal;"> </font>
                    <div style="line-height: 1.25;">
                      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"> </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ \P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0
MG S@GG' R1GO@<X^@/KTR: ;MJ+12$@ MS@#/0Y_+_([]*B$R$XPW;L#U..Q
M)_#J>P.#@6JNM5:]^EO7\?34:3>R;M_7ZDU% .1GG\00?R.#10(**0D*"3G
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M%)2V=[>O7_/_ "']_P _Z^3\U9ZH****8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 '.#CKCCZ_F/YCZBJQF;<(PO[SDLN'(5#P
MKY VD'_?'(*]0Q6PQ"@DYQP. S'DXZ*"<<\D=!DD@ D9Q9!(8]JB1=SLP5@P
M3 ^;>(PNW@#[Z#*$;05(27+WXPM\6O,FKI)J^C[[7L[=NHFG*T$^52=W4ZP2
M:7:VM^NFG3=.E:4L%B0/.&7=N$8$:$+EU<Q8*OMY!<N3\J@8S')),=PCV?O
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MJD.H^ =?^V:98_$KPQK$MCK?AZ\AO[>:_,.BZ6UH+F\11;LV9 $DD$@0F/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA*5-WM=N#Y6[J,59VLE:ZMKJPHHI"0H).<#T!8_@%!)_ &M!BT44PR*,\/\
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MWU=EIYNUO5=6D7**KB5=J.S.F1RJHQ7=F,L"6A# IRIR$(3SF=%,3>2]'W*
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M]U)+1)K^T@*A=%48W /E4 (W8)(/E.OS'@E6]OF)K5_SZ_SK'@(:.!AEI3#
M2"H*DF-?F+B-B21TS(<XQ@_=.P,X&>N.?K^9_F?J:_RGI?PHWM>+<&UUY;:^
MKOJ^]^UE_N?"S@I*5U*<Y6O=Q?NWBU]FSTM9;6MH%,D^XW4<?PKN/X+L?/\
MWPWTI](Q !+= ,G(R,>XK1;KU_KL5>VKT2U;]/N_-".2$8@L#CJHW,/H-CY_
M[X;Z548 '&T@_,1MB+>7D2?-'BT(8MG#YX&<#);#V1+&XR"2,$\HV,#J<%>G
M<'H001D$$TFDA19)3L14CDE=@@!CCC61F=,VF6)4DL#GALJ"&_>2Y*,H)M*4
MFE%-V<O>A913^)WMHN]^SB>76W,^C4-'S>GG>*7Q7TYH6/,D5B2&('5<2$ ?
M-@J5M@6)XW#)QQCL'E63<<%2#R>%D*XYP0S1J#P!D=B<<Y4M\>^,OVY?V8_
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M-NSCM-QNHZN6C6J@HN32>_NOS75>J[))S5D[*[TWM+E5^6_-9:-KIMHU$?(
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M]-Q<(N%W&R46]&TM%??M_P !;'KJ3FN9[RUZ/\4DK][:7VNM0HHHJQA1110
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MMI+FE;E5V]W=66[NK$E%-5U?.TYP<'@C^8&1[C(]Z=3*"BBB@ HHHH ****
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MK-$& )8 ,^UV( &245<'Y(V+*% )9 2 N @_=1RU!$$WRNK.2Y4LK9 !"XR
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MLWC\JV#B=!M)+Y\KS#APP!_=QMEG9Y4V N2TA3>[2*]S_-G_ ,%J_P#@G/\
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MHTVV];/1R]#)? ?-L^R7 YK#/JU%XRBYJ*4>62C.4-4Y)VDX:I--7;ND[O\
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M<B1"-S<O$&C2T_59R_FVXC56 =5<'(.U6C7[NP ,NUV^ZQ#1$?)L+6_^9O\
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MAHT09&-@ #8&W)QCE555'RX**K94DPQ2TQ&+ DKMY&/O<@HI.0R(0025Q@\
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M7C_/<>>JHJG2FYRGRQHTXN4FTK+3EE)Z:-VES:\MK-I9!);6R)+MBF24LRJ
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M,XE5-AD.CB/(\E9%<F,Q^6H?R/)D%AY=_P %$KV_TG]BW]J'6M&N9K>^T_X
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MHW!GX);5D SM5L84Y7@Q*H,'3?#:^^/\GQ=^$J-XC\3O+_PL/PTE_ ?&VIF
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M]9?TY0Q-'%0HXC"S5;#XBBJD*L6G%-*#Y;Q;C+F4^:^_75.Y+1112.D****
M"BBB@ HJ!M@=CD[AM9AMR NZ/YO]6W]T_-G)VD%AY0,4$KECMC*;"RJQ;("
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M3PAHR-XF\-^/[VX;_A$;/5K.W!ET7Q;H]HDDB:@[7+[%B)C5H?(57$'U(_\
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M]GQI_-3:6*S_ !9(/"1_< !5B P*E2]L J6O[>^(]2CT+P_JFMR*H?2]+O\
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M@J(L>Z#_ $B_$5U_:?P8\27K(F;CP7K<F41T^4Z=<9P)(C(A 4'E58%008B
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M6X5P'9QY'A^[=L>5"IC8')0!@P S&T07='_F _M7ZU/XB_:4^,=]O:X.HZI
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M2)+'6[N/38FAL]&\&V]DK:9-:7-H(_LWA,7:EIK:/S"UTVY]Q1=SEI??/CA
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M*U526UT!26_X27621M).#J8/)\HDY#=#)+N#;=DF[RKC^W;_ (-TES^SM,0
M0/CM\7G/W68 _#GX5@,Q$)/S%Q@ER<.1YIWD77]3^+L)K@F3<9)*E2BVTTD_
MJV*T;T2=[:.[\NJ_BKP+E'_7^&JN_P"T;:J_^^96M-.^FZ^>Q_3&P^8C ^ZQ
MQLR3_K.?^/<\<X/!R6'7=B6.Z'^C7/'2WN#R-NW,<O*GRTR3G#<C .=W.9'L
M/F(P/NL<;.3_ *SG_CW/ W8/!Y8<G=B6.Y(-K<D8(%O<'H %S'*<J0BY)!&>
M1@$'=\V9/XW?Q+_K]3^]R?I;[U\]G_>'V9_]?)?^DQ\WYO9=[?:/\XC_ (+&
MC=^UQHPP'S\$]#;!&[.?BG\:/FQLGW$[^&VR[R_^NG\[_B8?2O\ P;R#'[5W
M@[Y=O[CX['++G_FD=D<G]UT^;=C/W7!_Y:>9>?-?_!8U2W[6^C<!\_!30S@C
M=G/Q3^-!+CY)PQP^<[92V_/G3B4_;_I3_@WE4K^U=X/^1AB#X['[AD./^%2V
M8W?+"2X+-P%)R'&,^:)+S^R<?IX7N^G_ !CV.W_[!<1WO_7W'\'Y4F_&:G9-
MWS[)TK+_ *?X/1.T?NYH^BW7]]4 Q"G&WY,_*,D9W'</EY8YW'[V6)^9\[G2
M8=>.ZCIZF48SY9SG.,;FSNV['W^7.EN5\A",*-@/RD,06R000I#.VX'@N&9N
M&DR'=95)SA2?N]%SQ^]S_P LSD8)R-S9!QL?=Y<_\<TE:6UM:G2W_+RE_=C^
MORV7]ZTM)6[0CIVU?32U[?RQO;K:T:T PS_*P_>3-G&6YWG>H\H[L[LJ?WF0
M_P#K6\S==_QG?\'*//Q.AZG/[/OP2;D?,<_'KXO?.?D.0V[(.&P&9?//F[;S
M^S.%"&8X(!DD.[@\N'(;/ED9.XXW;SR2)7#AKO\ C-_X.40?^%I01D-N/[/O
MP3;YD89(^/7Q>W,6\LJ22PP!YC,7V),YG1+[]-\)W'_77+=5I4PS>FEG6AK\
M%GMJ[2\W*]G^1>,J?_$/L:[.RE'57MI3Q+Z->36GFK6O#^?O]C1<_M.^$?EW
M?\6\^+?1<_>^''C098>1+N#[L ;9-Q;/[_S?],_U&_!WS>#/"S<OGPWHK;F;
MS"V=(MAO7Y[O<3G!&^7<2[;IL[I/\N;]C2,G]I[P@I7D_#WXM #8QSO^&_C(
M@G_1Y0P=95(&)"?,7(G:=!??ZB_@YU;P=X6!RQ/AS1,LY+G+Z1;8(.ZZ&YLA
M2K22$E\EI3(IE^Q\=DUF.1-W5L'B(.^EI_68VB_>6K^SJ[[IKXG^>_1G5^&L
MUC:\GC8-1M=M.G&S2Y6_U7\T>GXX?\%UUS^Q%\5?ESG4O@1_!G/_ !?'21S_
M *,VX#?@C][D2%,'S_(U+_//NAF[U@;<_P"BZV<;<]8+GG'DR==_7:<^9]]_
M._XF'^AA_P %UES^Q)\5$"@L=2^ _ 4'[WQQTD*3BW8$?O,$'S.'9"#YI@U'
M_/-N65KK6"!D&WUM<[?E),-R,@M"P;<7P"H8N9"5:19'-_\ ;^!RYN$\S4?>
M?]H5GIK_ ,PV!EY]->EUWZ? ?2/UXWR]K7_A%P>O_<[F77Y/J^NB^U_IV_\
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MQ8_//NWR_P"=W\4(&D\9?%3Y&;_BLO%@. . =3N\/RN&!\SA=^/F7@[S'/\
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M)7'!P"VT9VX&V8=N_"G&, 8[_<'S#L,+SG@8PM5(Q&2-I.XJPRAVC&W[I$!
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M\!5(1E9'"G:S($7,MJ4Q9?R:_M)6\NG?M ?M$Z2T:":U\>Z[9%!S\\-S?_\
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MWMJUW/[CI6J*I*/OI\EE%-Z1C3YFK*[T;NN5[/XKZS'<"^%&3R#S\V !\W
M(&  6^;&-P&0O\07_!QU&B^.?A*T0S))\3/V@GD(6,G<FB?!?'(!8E'4C):0
M*54>9 T9%G_;R'WR,$"E05+;E8;CP!DE =R[3C&0-O).<1_PW_\ !Q1?K<_$
MSX>V>5+6WQ/^/*A3G!>31O@X%+,P9 /W./E!4-'AY(Y$;[/^H^$%._&F7IR7
MN?69R37,TG0K2BFKII-N/+=;2WZ'X]XZU8_\0\S9MQ2Y\/&+=DI?[9AE*SLX
MOEM)WT:M):J[E^,W[!,GE_M??LSR*N)9OCU\)B0%< [?%0((80HRE"@ .\%-
M@P592+/_ $LT4R? &_Q\X_X0;6U+ !LC[!.%)W1-@+C(W& *%#,L(4O;_P";
M+_P3WTM+[]L;]G9%#E[;X]_"!L#;]YO%;87)MP %"C*CRN4WDQ,C+:_Z4<\/
MV7X%:I P^:#P/K 9=N6 33Y\@_Z/Q@HWS;8^4R!"06A^Q\<:D:F<Y(KQ4U"#
ME"Z<DY8GGC=*WV6IK5W5WKI)_GGT<(U'D7$;<)QP\I35.JTXPG?#QC9.]I-.
MZ?;F23;DW+_.*_X*=J@_;7_:&558E?BGK>X ;6#"RTX-@F)2 K*<DM$<J5P@
MC"0?LE_P;6#_ (K[]HKAO^14_9]'W../%GQ6&#^XXVXV@97H3L7;^Y_&C_@I
MN _[;?[1)&]F7XG:TT@VE=J"TL-FS"# 0HPW97"*JYB6,K!^S'_!MBOD^/?V
MA3)D"7PG^S]L(4,IV>+?BLI#%83MV\  E1WVJ5(A^]XKFI^&4-4V\ORM6TNG
M"O14ELVW%)7=D[6N^A^;\!.,/&1IRBN7-\Y3;DE:V$S".K<E]II;M7DE:\K3
M_M-(^9?E RPYQU^H\OC&.G/3.T8W1UIU -MC)WN<ET^<XV\ >1E3WXC7@= %
M!2=\+M8KQD=%)8X]5\L$=.!C&!G:-I:* _O6B*X<(PSN55(YQ\P\@@$;>0%4
M\ D8 V?Q]34G032;7M9O17NO;IW[62NV^BTNKZ_W9S6K58V_B3C#JE_#YME9
MO:^D7WYK:R^=OVO)&_X9M^.'EAACX1?$4*=I5\_\(W=$=8P4((_O)C!+[<%X
MO\P?XR+'/\8_'TTX<,U];+*0CC[MNA))%N[$KC()QG&,*%_=_P"H/^U/9KJ'
M[/?QMM47?(WPG\?QXX WR>';L*"YA.S:8R205"X!8KL_=_Y@/[0-A<VOQX^*
M^G^6 ^E7-L\T>Y/E46O)W(@#9V$$Q[1A5SLVGROZ6\ L104,ZFY1G3LU*=TX
M7O!2BWMS*TDU=V:L]S^3_I-TW*KD4%-0IT\)4C.[5DYXFBJ;;EI%RE-*FFVY
M-V5KKF;X>^,_Q6\#V-OIG@K7=2L-*$(M$,&M:[IS-:QNTJ*8K'4K&,;9)&,:
M^2J(20$1N4ZIOVE_CPD BC\8Z\^5=&=_%7BMG(P>\>M@J,@ACCW&,'9_4M_P
M0R_9V^#'QI^!VDR^)[*:\UJ+X9^'M2OP-*\/S1)-/XDUFW4QRZIX=U!YMR0(
M&^>4X4!G3""/]W'_ .">_P"SO<-DZ/*75ED*C1O J[L *$Y\%C*X&"!QP5)!
M V>CQ#XK<-Y1G>.RG'9'AJDE4O3G)M2JQ_=S]SFA>::=U;K=I--N7A\/>#_%
M&=\.Y5F65<12P]&5.7-0J0]JH\LY4I7Y*]!_$FW:+3;>KUO_ )P<7[4'QOB0
M0'QGXD>8@K(K>)_%A56X4*A.LH.,<D%@RCD9'R"_M-_&TNZ_\)KXD>2V^?8_
MB;Q5L;GKSJ_*C:-Q7:,_AL_T?T_X)^?L\12.X\/EG<!2'T/P/M')8#GP8A"D
MG!^?Y0 %VX^6,?\ !/S]G:20R+H)#LZLZ#1/ ZKQ\O '@T-P>%&XMUSU^7R7
MXP<(UN64>').,.6%J<)V4HQC"5W[%[M-RU6JL[Z,]C_B!'&SLWQ92A3D[J+B
MZ2;E;GLI8V4M9-M^=G?K+_-.\6_$KQC\2[B*3Q?J5SJ-S9W'V]&N;S4[_?<2
MH("Q?4+F]8@QJ(R05D(RI+*/E]U_8ICU"Z_:;^&[V<,/^C_$;X<37:;=GEP+
MXML5^4,J^8 1]T%ATR"#FO\ 0[F_X)Z_LXF9IFT:9'D(7;'HO@=1D=!A?!1V
MD8R.<Y'7K71^$OV(O@7X*UEM=T/1#]OA>TN(FGT;P=&JS6%PMU;LCVOA*UE4
MK.NYBLNW!R&1OFK3&>-V23RS%Y=0RFI1^M4)4+M3C"%[34I?NERM.,4]4]4K
MR=D3E_T>,YPV<87-,5G=.OB*56$N24$I./M(2?)?$2O>U^7ED^]X[\3^V1J$
MY_9A\:W-NJ8E\'?%!6&Q@@1?#>IX'^K.T'&>2@YSM8?-7^9UXH+WFNWXN1Y9
M6PT]PL*9+$VD2A'#)+E&4Y8AESG=\Y^5O]/S]L_PZVO?LZ_$M!&4DL_A[\0K
M@Q6QB@4/)X5U!0IW6S@AFYX*C^(9X8_YA_B6TDM/$6L6$L:FY@TK3UE3"NIW
M6D14JXA92<, 2&W,3RLA)W5X(3CB<#FE-U(^SJ5:=2*B];)5Y7UN])2L[)N\
MFVN_/])2C*EB^':L:<[TJ%6BZCBTF[X2S<[J,FXQ:C)Z;[ZG]HW_  ;H6\0^
M#FE7"Q@2S_#+48Y"1@.J_$"+ SL+.>!P?/VC&U0"=W],4*@W-QE<CR_NE0 P
MW'L80>/4!\9&60'#_P P?_!N3J]M)\.(M%W,]W9?">^EGC,<@11)\0;=4 D*
MLDC?."P59&3/2,'Y_P"GQ6B5YE(!9TVG*MASU7+B)LX!X.T\GH"<O^/>)'-+
MC/&M7E=44[>\KI4VU=.?PK=6>RUMO^]^$?*^!,LT48RAB6FG:RG5BT^;E^TF
MVFG)-7T=M=%,$ A1@CH1][!/#Y0$8['G/7/.6)AN &-V=WRE<HWRGASY4NT=
MP<+DX'S9VEL>%14/55(9<9'4GDB,9QG)(4G)Y))R[G'FJ-H##!^5P K@@@ E
MXI#CO\H';.5.#\:DUS7O_%FU>^L5)*^K>EK7>J]=C]&@DHKEUBDES*S3LK/5
M*SUOI9]G"5[2C<9C[GB3EDP>2PP1Y P#T!PN1@Y?.6\?^/(_XL_\0!@'_BA?
M&(P1QSX<U+@G9T.>N>0?^6N<2>P2<)@Y)PXR8\YSN('RP8&1\H^Z3QR['YO'
M_CP,_"#XA*%#%? OC % K'.[PYJ0QE8B#G.#SSNQ^])VR;9=&?\ :6#;C*WU
MB&MG:_-'KS6[?GKNN#,E_LV-B_BE@ZZ2>[?(G9:2;=M;*3;\^O\ EC?$\?\
M%Q]4_P"Q>\-=5P3NT73NWE#EL_W/GS_R\;LR_P!CG_!N=_R3K2AA?^2<_$$
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MXXY'7#1*QVBU"J 4?(VKAX!]EN! 0K2 J5VEL*-H\MXRIP8MNU@%+,=I7:"
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MV2"-[;MY_P!<6'GS,0P9L9&&P54ON 6?!&('+;@00!NSN^4,''GLB"LL9P&
MC7Y@H;&8Y.0?*;)*MTWG(;J0W[VPH*A\#DL[8SQDDD=%&W/!.$ZDL?,8EW_C
MM/E<;-6O/>RNO<=[Z*UXIZ;*VMC^\XWC5<E:TJ<$UIHULWL^^DEKNFDK*C"[
M%F(4$EV?E6&0$(5@WE.<ON!V@L=L@)=RP-W_ !E?\'*9#_%BV&.6_9\^"DA_
M=@9 ^._QD8MGR6S\VT'F4J)""9#,?M?]ET$;%FW#<0\K'C&<KD2 ".4XD))P
M&*N"?FE61C>?QB_\'*3H/B]91L""W[/7P6/"XY?X\_&H*P(M')/WE5AYI+3*
M 9/.(OOT?PEBJG&&"BWR<_L8*>RBO;VYG)M7Y4KW<OY5)VU?Y%XSRG'@#%TU
MM.5-6O;6<:\;V71.2[ZQ=DME^"/[%\3-^T_X.; 93X ^*@Y7/+_#_P 7([;O
M)<DE798E42>9)(5"S/<A=0_U#O"7F?\ ")>&BJJY_P"$=T#DY WC2+78-P24
M_,3M*[GR'/ 8B.Z_RZ_V,[<-^T[X/0 N6^'WQ3VYYR%^'?C#(!6%U!V,RXP^
M6D2+%WYD<=__ *B_A 2-X.\,;54D>'M"R2WS#_B3VH)&5GR<%<KNDR&<$2J/
M+G^Z\=*<:>8Y):HJO[NO:[Z>VC9NS>ETWZ?-OX'Z,\94LFS.,V_=Q=*R5GO2
M:=M]7II=V3Z)'XZ?\%TS(/V*/B:HC3#:I\!BW[O)^;XX:0CDMY+@EA(,1@RD
MR.8]DHF$=W_GH31R&?63M4[EUA02C8=C#<$<F-PK,)54_,<B3<-RR 7G^AE_
MP72A8_L3_%"0J IU?X"( %PC-_PO'1R69_(?)429*,'4&4@K*)6@O?\ /+N)
MRL^J@;6!.LLH";LGRYE5B1$<!B<<,V\2%E#F8"_^R\"N9<*9G+92Q]5WL^F"
MP2=GKUCS1LW=I<NBC*/YU](B%1\:X1V;MDF$<6U=)+,,RLK)*R7NKO:;LE>S
M_P!.?_@G)YL?P!0A59VU'PTV#D?*WPM^'S%L+YI&X\@'!VL#NE8JT_Z"U^?/
M_!.@,_[/\>%5B;[PT>0I !^%7@!-P!2098'H V48LKW",/M'Z##H/\_X?R%?
MS/G_ "O.\T:M=XMW2>NF'PZ5ULO+1/>]]W_8/"FG#V51_EPJMI_T]J+>RNG;
M35];O6Q5N,C<0,D*,$ID*2)5RA,$F7.=I7<Q (Q&2WES?,W[87R?L_>+#M
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M=@I.=L1F6J]YZ1PE]-==D]GH[:W3_I]_X-O&=?@M\6!Y8X^/EN?F0@G;\&?
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M_P#P<)_M+JAW^$O@9@*,_P#%'_%@;T4Q9/\ R51-I 08"[5&P8\KRP;>9O\
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MZ5^62UE_7,5#G) ,H&0NT;2^?E&3&Q4=]HV@'&6!&0QXP64SHT>2 HC4D.W
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MKF=KI)JU]/ZV2(96/EDM(1\ZLIX3(&.8&R1N&0.?GS\VX;DN#!"NUMRAR5&
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M[W>KMZ.-[H_D?P/4UXD8R52#45AZJ7NRLK5Z5[7VM:V]W>[U6G]12,26&,
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M)V3BEYV,RO 9C0JX;,\'1Q-"I)RY*U.$E._-*.KUNHMV=XM*^M[V_';XG?\
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M[1^:'[0MY/XQ^*0NKV.WMKW4-/\ #&F+#I\36]LQ<-;P$I,+@QL[S_.VX*2
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M)U?Q/J^L1X@N_#<\P417R@*7)VNJN9YOWEU_8ZJK('!0+\V5*C<PR&P=WE,
MWS$MP,%BIWJ=TC3&#D&.(]MP13G.?F.5')WL2,$9SRP8;N#ACBS.^&*M>O@(
M49U,0J<,13JSER?N5:'NQE%:*3FK[.7NK1';Q9P1D_%>'P6&S2&,]G@G4=!X
M;E]I!UI4Y3UG2J2UY(P=XM:/K(_'+_@E#^P%XA_8?^'_ (R\.Z^FJ";7_B1;
M^+T.H^(_#OB)P@\!^'O#+;9M!T>P2-%GTMT2*19)W?=-YIC=!)^QLJJTT4@!
MW;&*J$)5L%LL0802WS<DO\O&%!8B5 B\MY:!5VY"QJ<Y#Y)40N6;YL8#CJ=H
M)8^;*$R3)(  N"N$4G&UNBF-VW?-PHP<G"@EFW\&<9IB,YQU;,<>XQQ6*=Y1
M@].:,5RV;N[I<J:=_AC&V\CU\ER/"9'E.'RO JK3PF!BHT(UG%5(Q4E)JSC!
M*-]5:*:4FM=+<IXJ\.:1XGT:]\.:XKR6&IO;S7$<4,4S,MM<1W$0"7-E=6YS
M+ F])('9@2 QW9;^5W]N?_@@%!\1O%-UX^^#DGCBYU.YM]5OIK:]\>?#;1=-
MDU/5O$]YJ# VS>!+*X,:6-R#"[7321N!$]S(5(E_K.91*"2H.S.#@$E?F((!
M@+!B#R@'<@;@3NB='DD0"&%X0K%BR@_.0<?*8C@D'@A6ZD8 (+]_#?%6=<+5
MO:996E3=2I"=1./-2J2CRN'M%&TK2LHR:EHE'6+1YW%/!^1\78>#S'"TJ]:%
M)T%BK*5>G1D[2Y&_=C*'-.47*,K2]ZSYFC_/AUK_ ((,?M?Q7<,%GX3T^1(4
ME EE^*'@3SF5)&5'9A:AF=E(W@C).[=DD>99T[_@@G^UYJ%W:QZGX9@ACZ'[
M+\3_  *"56,ODYLKC)#8!4I@C&T9.YO]!@VEH03):6V<-@>1&_7DG)A!RQZ@
M CIP355K2$R QVMNI' VV\2!C@@DDP$C(X.2  ...6^^7C9Q/"B\/2IY33E*
M5[JG6NYRMJW]:T;:2O=;VM+9_EG_ !+SPI.HJGUW-O9+W5357#<JA+XDE]6;
MLTWH]K^5C^6__@F3_P $5/&W[*WQ8T7XL>,Y/%%C/I'BQ=>2W3Q_X&UG3;B*
MZ\,RZ9*]Q:Z3X8BO9A'<3E84^V*XVAB[KN+_ -1-A&R6]I!$JR):0I!(\@'G
M9C7"L"(U#9 !R$P3DICD"]+F)!&D432L#MC"?(PR<G*Q#G&=XS@#GN U&Y5+
MF/RXB%N-H 2-?+0G(+'?Y39  /.X#& _!*G\UXCXES+B7'?6\UK?O$E3O1CR
MTH05FXQ3E-QC[[E-N4KN4EHK(_5^&N&,MX5P4L#ET'.$I.<Y5YMUJU1J,85*
MDH*%Y0A3A"/+"-HQA>+E=RFC:5&<3*K1NQ);;N8+MZG:K@$$="I!Z$XYK^>3
M_@OWXO\  6D? KQ)I&MM-'XGU3X4ZI+H$8TUKB-X8?%NG).TEW_9\HMR''")
M<)D8QP#C^AZ,M##^]17,1C7E6; )&&R$PK*3U!1".<]*_P ^7_@N#\<M3^+?
M[17A3PC)<H;'PU;?$WPI<I9QZI9N8D\;0W"&47MW>V\\@\H RK ( I(\LL01
M]IX399/-N+L#/#*7L:$J;E-)V:O46MM$K+=NR5]-4G\/XS9W1R;@O,(8J%.M
M5Q\?9*BY7?(Y48SG&*4I2G2ISE."2M>-I=Y?C3X7\(ZG\1/&>D^$-%B\R^\3
MSW,.G0FXCLUFVQ23)NFN5\FW^5>3+@$9  XQ_I)?\$O_ -FO3OV??V=/"8@6
M\;4/'G@WX=:YK:W=[I%]%#J>G>');25+"32M+L66)3<,/]+:\G?C$ZH&5?XX
M?^"*_P"SY;_%G]J+P#XHNX;B?3/ GQ+TW2+KRKK3HAY=_P"&]1N 9;>]TJ\E
MNI%V [[<1(@XDC/#+_H6>&-*BT'1M+T.&,+!I5C:6-N#LR(K6)8D_P!3;PQ;
ME5>?+CB0$?*JK\J?9^,_$:K8N60X6:="A5INM%/=P]E-<J5TO?3O;F36RC>Y
M^<?1UX7C# 8OB2M3C3JXF;IX*<HV=2FZ:=26MKITZDH6=^5*5GJ[ZTD1+*54
M\ DX7 (^7@_Z./P4,#Z 8W*0P,OS$$DL&^=N<'&>L.[('0;5;( +@\1W\ =!
MUY/N?6BOP-1482II)0E\4;:/U[Z:.][K>Y_4D%ROF=G4Y>5SMJUZV[:$!W#[
MJ\DC.0V!P.<",?R.2!DC&59*2$WE0&&,_*&'0$DEHE)/_?(X['[JRJYEC8!3
M&,[]R@L"I#*R9C8DC'&T\G@;3\ZQ-&?,4A0T<N6<,JA@<*58#R P8;>AR^>&
M  #)#2FI0A[DDX\TEJ_=C&6OG962]+Z;CY5*%XI03UB]+\S6J>_Q-+MT6]I?
M _\ P4$_9GU3]J7X!_$#X9:-%=O-XI\!:_X7/V+4M)T>Z$NJRV,D9CO-5L+F
MUA;%J2)9HWB7 5HU.UXOY6?^(<?XS#5;Z>VM_$TD,EZTL D^*WPV5FA5G,;,
MB^&82@5<\$* JD';Y;&#^Y[RFP2J*3T!=!VY'RLB9Y(]%!&1T^1T<,:J T2!
MSAFPBD9&W<V1%@-QQT+!?X=N$^TR#CK-^&\&\)@:^'5.<N>4*W.XN?-%\VE6
M#YKVNW*7NOX5N_@>*?#/AKBO'/'YM&K.;I0I0]C."GR73<9N5*K[CLG%*,7S
M+XM;O^&H?\&XWQK27SA8:\[!1(0?BC\-,%E+,!@^%XV R%S$Q#Y .5$;_9T/
M_!N1\:I7#M8>(8P!\X7XH_#9=RXR0 _AACM^51Y>00W/R^4QM_[F?+BX^1>Q
M'[H#Y1MR3^YX88X7K\O48^5!'%@$(O.",Q*OR_)DMF$;7^7[C8/!Y7;\GTR\
M:>*X252.*P*DHN+DH2<N64>5Q25=MMQDU:S;O9=4_FH^!W ZY4J>.<8KE476
MI.-M+PUP5[--Z7;:=NNO\-L?_!N9\9PJQ_V=X@QR,M\3OAL#M(P &/AD%2-S
M#<QX*Y)C$9-M$G_!N5\9A*%:Q\0(LC#./BA\-8R0"FYT5O"X"84OG( C$/W8
M\'['_<H4@C)!0#D'E,@A2A)!,.T,,$X!'"_> C/E.$43C.P 94C*",D83D@P
MH0P Z$#!'WE9?W<KQKXK34HXG"1LM&J%;1VLY+]]O9JS3OYM-77_ ! C@/KA
M<8UIO5IM77+K9X:S=UKO=ZZN2O\ Q;>!?^#;?Q/+=M)XQD\>65O)-8N'TOXG
M?# SB!6G^U.HE\$W1B>(B#R 40L=Z%05"V/ZU_LJ_P#!##]GWX*W.C^(-:U7
MXIZCK>E3>$=26TUKQ#\,=<TJ34= ?5))[>6.U^%]M+)92/<P"58[F)IML02:
M-H5-K^[,R(!M*#!RI*HJM@",C:?*7:P\M<%2<;!C;LW0I"(H\')!8H,,/[FP
MC ^S@ @9)/RL C;MGE,(?#S/Q,XMSJ4N?'U(1<8\KPZ=.,$HQ7N<TJEMFY7;
M3<VY7YD>WE/A%P3DM:EB*64X>I4@Y<M7$)3JMOW?>=H1:2:A%*"2BXZW5WP_
M@[P'X=^'^CV7AWPKI-G:V5C96&GHR6%A;3SQ::SBR,ITVRL+9I(1-*4:-(8X
M?F$*VRHYMNR2UF;(90B9&_&$!'RX\O$2D%% (; 4$*J&-PILK;.Q.88HV^8%
MRRN'/RIM)!C7#A@.22 8@A*D,T*2).ZQ/MC!'S2;L8RNQT8AE7)!3N4Z+@0R
M%9;?X:JJN)G.KBJLZF(JM3G4J.\IU'RRO)VE?5*_+K9KW=$W^B0HTZ%-0HTH
MT:%.#BJ=--+E5WRI-I6=[M6UO)[?%\X?M8?"2Y^./[/_ ,8?A79-.LOC;X8>
M,_!2M9W=CIMQYGB+2ULX6BO+^SN+&VEC>)<3S1&T@*[Y%C*A[7^0OQC_ ,&[
MOQDUKQSXWUZTT_7FTW5-=O-1MW/Q/^&]O(]JS[E/V9_# :"7:KG8RQ%#%&<0
M;9#8?V_M'   X;<P&Y4&Y?EV Y;R4 *.<1Y"?<& BP8@##$"VR-68%0H8*-X
M!3Y2OD@#;MDPA(3"+AT$0-I]APQQOG_"V'KT,#&E[/$0G&HY\RD_:<G-)*$H
MMSBE:"LTG'WHM*Q\3Q5P)P[QA6H5,RJ3J5,/&%.FN:+BJ<9NJJ6L'>$I2<FK
M\W-/1IS][\XO^":_[)FL?LC?!C1?!&OK?+?Q?#OX7^%[O[7K&E:UMO/!4GC=
M[D1SZ-I]E"&3_A(8G:;R_)D41FV^SM;SB#]&B (68*QCV##A-C",$DXVJGE$
M H2%\L*RC/D;7-K()%PD+1IY@*QA@FY=XV[2 L:@[3%N.W8 8AQ'Y4QM9XPV
M"LD:[<QM'A,_<*JI8"-0K*51ERH( ##8%*1?,X['U\TQ^,QF)?M/K%2,Y;\M
M624+-=[*-KVO)*.CUYOK<IRNAD^!P^ P[BXX.#AAEIS4XMN5DE=M)S;U<DHN
MVC=WQWBOPIHGCCPSJGA37+&WN]*U[2-0T2^,EK:3W"66HPBUNTMUOK.XMTD:
M-!Q+9F)7MH]\*")EM/YO_P!OG_@@GX3^,.M:Q\0O@_<>/W\4ZMJ/Q(\2WFE2
M>,?AIX>\.1ZGJMIX4'AVPM[63P!:7$6FM/I^J;X9-3DDM8H(2+BV,Q-M_3.J
M2(TK2(BPHJ"(HH5S$"N1@*/*<"*,Y41@ +ED*(MFH164^6OF%B"T<BJ5"C8!
MD>2NT%T"@-A@L:H?*$/^B]>0<29OD&)CB,JQ$,/)<T52E)K5I0:DN=2?6335
MW%\NB;;\?B/A'*N*\-'#YQ@_;**DE6YJ?M8VJ.=TI0FG?GY;V:>F[>O^?[K?
M_! C]K;2&NK?3O#%NR*T\5M)/\4/ @E,=LJM&\ACL;;8X;DG$!_<;P8C&PL>
M*E_X(5?MJ;A:7/ANRCACW10M#\5/!1D*O@.S(44?NTAC*<(H(+_NVA9++_0U
M>*S(5IK>'>&.,01M@;HRQW/#\NTQH,Y4GRP[B(PD0(+6P !^R6K)A>MK$K8P
MF 5\L;"HCCSPJKY*GY5C8V_Z72\:N+:7+)83+W6C\563JNI)6U;DZN^JN[).
MU[7O?\KJ?1YX)I5%7^LYY#VDU:$:^'=%3:LE"*P*E=KF2]Z3BI--7>O\#WPV
M_P"#?K]IO7[VWL_$FASVVE7%SI4-Y<Z=\3_A])?0V$\\T-]<V[3Z1<HMS%%'
M&\*26^&DB)= 8E6R_?/]@W_@B)\(_P!F>ZL?&'BF]^(M_P",47P#JCZ?KWB/
MX;^)M'CUOPCJ/B&^>"(67PYM[M+:;^U(5O"M^CW20VZQW%K+;EK?]]$MX-H$
M5O!"OR<QQB%L 1XZVRLI50ZJ5*E-H *-S$;8H]BN2&++M7;N0L@CR<BW4?(%
M)!P% !/R+$HA\#._$OB'/J,L/4QE/"TYN+G1H2?O6<)6E^]E)*ZN]VN9N]F[
M_4\.^$G"/#M>.*HX7$XJNM57Q4J<KMMN,K0H0M:Z6F[BK)W?-E:=H=EHNF6V
MF:9;1VUG8PK%;01Q0PQQQ1B,I$L,-I;V\2J2P54$:H%&TQD![>TI?(7R5(+
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MGB1'3*MV:@AG8JHW;>0<DX&/F^13QVRS>V.E1SH70CJ-K K\O((QCYHI?J,
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M\I9EM+@+)9O+MW':9%VX5 P#@B!2&WC .%.4)^4(?+F&^:/RG549"')7/FJ
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M ,+\G?M#:3;VFJV-Q8&9I;34O#%\3,%!\N&43%7=+>+>N8P!&CC(/S/N%?4
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M4 *A2K%F&(F8M\QP"20O*^=N99YGCD.,*IX.<(%YW#UC!P1DXPV,$?-D![P
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
